BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) has completed a Phase 3 clinical trial for NurOwn as a treatment for amyotrophic lateral sclerosis (ALS) and in November 2020 announced topline results ...
On May 19, 2025, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate the Phase 3b trial of NurOwn ® in the ...
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The ...
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At ...
The average one-year price target for Brainstorm Cell Therapeutics (NasdaqCM:BCLI) has been revised to 2.55 / share. This is an increase of 150.00% from the prior estimate of 1.02 dated March 28, 2024 ...
In a challenging market environment, Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) stock has reached a 52-week low, trading at $1.45. The biotechnology firm, which specializes in developing ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
1 Day BCLI 2.99% DJIA 0.11% Russell 2K -0.97% Health Care/Life Sciences 1.02% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results